Literature DB >> 26893477

Activation of the MDA-5-IPS-1 Viral Sensing Pathway Induces Cancer Cell Death and Type I IFN-Dependent Antitumor Immunity.

Xiaofei Yu1, Hongxia Wang1, Xia Li1, Chunqing Guo1, Fang Yuan1, Paul B Fisher2, Xiang-Yang Wang2.   

Abstract

Melanoma differentiation-associated gene 5 (MDA-5, IFIH1), a cytosolic innate pattern recognition receptor, functions as a first line of defense against viral infection by sensing double-stranded RNA. Ectopic expression of MDA-5 has been shown to induce cancer cell death, but the mechanism of action by which MDA-5 exerts these cytotoxic effects is unclear. Here, we demonstrate that ectopic expression of MDA-5 via replication-incompetent adenovirus (Ad.Mda-5) initiates multiple signaling cascades, culminating in cytotoxicity and type I IFN production in mouse and human prostate cancer cells. This intrinsic dual activity of MDA-5 required the adaptor protein IFNβ promoter stimulator 1 (IPS-1, MAVS) and could be functionally uncoupled. MDA-5 lacking N-terminal caspase recruitment domains (CARD) engaged an intracellular death program in cancer cells but was unable to efficiently stimulate the expression of IFNβ. In contrast to cancer cells susceptible to MDA-5-mediated cytotoxicity, normal cells were highly resistant and instead developed a robust type I IFN response. Strikingly, intratumoral delivery of Ad.Mda-5 led to regression of preestablished prostate cancers and development of long-lasting antitumor immune memory, which was primarily attributed to the activation of tumor-reactive cytotoxic T lymphocytes and/or natural killer cells. Using the CARD-truncated MDA-5 mutant, silencing of IPS-1, and antibody blockade of the IFNα/β receptor, we further demonstrate that type I IFN signaling was crucial for in situ MDA-5-induced protective antitumor immunity. Therefore, deliberately targeting the evolutionarily conserved MDA-5-IPS-1 antiviral pathway in tumors can provoke parallel tumoricidal and immunostimulatory effects that bridge innate and adaptive immune responses for the therapeutic treatment of cancer. Cancer Res; 76(8); 2166-76. ©2016 AACR. ©2016 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 26893477      PMCID: PMC4873369          DOI: 10.1158/0008-5472.CAN-15-2142

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  38 in total

1.  Evolution of MDA-5/RIG-I-dependent innate immunity: independent evolution by domain grafting.

Authors:  Devanand Sarkar; Rob Desalle; Paul B Fisher
Journal:  Proc Natl Acad Sci U S A       Date:  2008-10-29       Impact factor: 11.205

2.  Structural basis for dsRNA recognition, filament formation, and antiviral signal activation by MDA5.

Authors:  Bin Wu; Alys Peisley; Claire Richards; Hui Yao; Xiaohui Zeng; Cecilie Lin; Feixia Chu; Thomas Walz; Sun Hur
Journal:  Cell       Date:  2012-12-27       Impact factor: 41.582

Review 3.  Interferons, immunity and cancer immunoediting.

Authors:  Gavin P Dunn; Catherine M Koebel; Robert D Schreiber
Journal:  Nat Rev Immunol       Date:  2006-11       Impact factor: 53.106

4.  IPS-1, an adaptor triggering RIG-I- and Mda5-mediated type I interferon induction.

Authors:  Taro Kawai; Ken Takahashi; Shintaro Sato; Cevayir Coban; Himanshu Kumar; Hiroki Kato; Ken J Ishii; Osamu Takeuchi; Shizuo Akira
Journal:  Nat Immunol       Date:  2005-08-28       Impact factor: 25.606

5.  Characterization of prostatic epithelial cell lines derived from transgenic adenocarcinoma of the mouse prostate (TRAMP) model.

Authors:  B A Foster; J R Gingrich; E D Kwon; C Madias; N M Greenberg
Journal:  Cancer Res       Date:  1997-08-15       Impact factor: 12.701

6.  Proapoptotic signaling induced by RIG-I and MDA-5 results in type I interferon-independent apoptosis in human melanoma cells.

Authors:  Robert Besch; Hendrik Poeck; Tobias Hohenauer; Daniela Senft; Georg Häcker; Carola Berking; Veit Hornung; Stefan Endres; Thomas Ruzicka; Simon Rothenfusser; Gunther Hartmann
Journal:  J Clin Invest       Date:  2009-07-20       Impact factor: 14.808

7.  A multifunctional chimeric chaperone serves as a novel immune modulator inducing therapeutic antitumor immunity.

Authors:  Xiaofei Yu; Chunqing Guo; Huanfa Yi; Jie Qian; Paul B Fisher; John R Subjeck; Xiang-Yang Wang
Journal:  Cancer Res       Date:  2013-01-18       Impact factor: 12.701

8.  Human cytomegalovirus directly modulates expression of chemokine CCL2 (MCP-1) during viral replication.

Authors:  Stuart T Hamilton; Gillian M Scott; Zin Naing; William D Rawlinson
Journal:  J Gen Virol       Date:  2013-08-12       Impact factor: 3.891

Review 9.  Dendritic cells in dengue virus infection: targets of virus replication and mediators of immunity.

Authors:  Michael A Schmid; Michael S Diamond; Eva Harris
Journal:  Front Immunol       Date:  2014-12-17       Impact factor: 7.561

10.  Induction of IFN-beta and the innate antiviral response in myeloid cells occurs through an IPS-1-dependent signal that does not require IRF-3 and IRF-7.

Authors:  Stephane Daffis; Mehul S Suthar; Kristy J Szretter; Michael Gale; Michael S Diamond
Journal:  PLoS Pathog       Date:  2009-10-02       Impact factor: 6.823

View more
  17 in total

1.  Overexpression of PSAT1 promotes metastasis of lung adenocarcinoma by suppressing the IRF1-IFNγ axis.

Authors:  Yung-Chieh Chan; Yu-Chan Chang; Hsiang-Hao Chuang; Yi-Chieh Yang; Yuan-Feng Lin; Ming-Shyan Huang; Michael Hsiao; Chih-Jen Yang; Kuo-Tai Hua
Journal:  Oncogene       Date:  2020-01-27       Impact factor: 9.867

2.  Targeting the innate immunoreceptor RIG-I overcomes melanoma-intrinsic resistance to T cell immunotherapy.

Authors:  Lina Such; Fang Zhao; Derek Liu; Beatrice Thier; Vu Thuy Khanh Le-Trilling; Antje Sucker; Christoph Coch; Natalia Pieper; Sebastian Howe; Hilal Bhat; Halime Kalkavan; Cathrin Ritter; Robin Brinkhaus; Selma Ugurel; Johannes Köster; Ulrike Seifert; Ulf Dittmer; Martin Schuler; Karl S Lang; Thomas A Kufer; Gunther Hartmann; Jürgen C Becker; Susanne Horn; Soldano Ferrone; David Liu; Eliezer M Van Allen; Dirk Schadendorf; Klaus Griewank; Mirko Trilling; Annette Paschen
Journal:  J Clin Invest       Date:  2020-08-03       Impact factor: 14.808

3.  MDA5 Induces a Stronger Interferon Response than RIG-I to GCRV Infection through a Mechanism Involving the Phosphorylation and Dimerization of IRF3 and IRF7 in CIK Cells.

Authors:  Quanyuan Wan; Chunrong Yang; Youliang Rao; Zhiwei Liao; Jianguo Su
Journal:  Front Immunol       Date:  2017-02-24       Impact factor: 7.561

Review 4.  Innate sensing of cancer's non-immunologic hallmarks.

Authors:  Ruth Seelige; Stephen Searles; Jack D Bui
Journal:  Curr Opin Immunol       Date:  2017-10-12       Impact factor: 7.486

5.  Differential Induction of Immunogenic Cell Death and Interferon Expression in Cancer Cells by Structured ssRNAs.

Authors:  Jaewoo Lee; Youngju Lee; Li Xu; Rebekah White; Bruce A Sullenger
Journal:  Mol Ther       Date:  2017-03-31       Impact factor: 11.454

Review 6.  Mechanisms regulating immune surveillance of cellular stress in cancer.

Authors:  Ruth Seelige; Stephen Searles; Jack D Bui
Journal:  Cell Mol Life Sci       Date:  2017-07-25       Impact factor: 9.261

7.  Engaging Pattern Recognition Receptors in Solid Tumors to Generate Systemic Antitumor Immunity.

Authors:  Michael Brown
Journal:  Cancer Treat Res       Date:  2022

8.  The Role of REC8 in the Innate Immune Response to Viral Infection.

Authors:  Shengwen Chen; Qian Liu; Lini Zhang; Jiahuan Ma; Binbin Xue; Huiyi Li; Rilin Deng; Mengmeng Guo; Yan Xu; Renyun Tian; Jingjing Wang; Wenyan Cao; Qiong Yang; Luolin Wang; Xinran Li; Shun Liu; Di Yang; Haizhen Zhu
Journal:  J Virol       Date:  2022-02-02       Impact factor: 6.549

Review 9.  Promising Targets for Cancer Immunotherapy: TLRs, RLRs, and STING-Mediated Innate Immune Pathways.

Authors:  Kai Li; Shuai Qu; Xi Chen; Qiong Wu; Ming Shi
Journal:  Int J Mol Sci       Date:  2017-02-14       Impact factor: 5.923

Review 10.  MDA-9/Syntenin/SDCBP: new insights into a unique multifunctional scaffold protein.

Authors:  Anjan K Pradhan; Santanu Maji; Swadesh K Das; Luni Emdad; Devanand Sarkar; Paul B Fisher
Journal:  Cancer Metastasis Rev       Date:  2020-09       Impact factor: 9.264

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.